Why the study?
Does chemotherapy with methotrexate, 5-fluorouracil and cyclophosphamide alter hemorheological parameters in patients with breast cancer?
Does chemotherapy with methotrexate, 5-fluorouracil and cyclophosphamide alter hemorheological parameters in patients with breast cancer?
Chemotherapy with methotrexate, 5-fluorouracil, and cyclophosphamide significantly increases erythrocyte aggregation in breast cancer patients, an effect also influenced by tumor volume.
Answers are grounded in this paper and cite their sources.
May elevate thrombotic risk during breast cancer chemotherapy; hypothesis-generating for hemorheological monitoring and requires prospective validation.
25 patients with breast cancer after primary surgery and 10 patients with metastatic disease were investigated regarding hemorheological parameters such as erythrocyte aggregation, plasma viscosity, hematocrit and fibrinogen during chemotherapy with methotrexate, 5-fluorouracil and cyclophosphamide. Erythrocyte aggregation increased significantly during the first course of chemotherapy and remained elevated thereafter. There were no significant changes regarding the other parameters. The influence of tumor volume was much more important leading to significant differences between the two groups regarding erythrocyte aggregation, plasma viscosity and fibrinogen, while hematocrit and total protein concentration were not different.
No takes yet. Share an insight, caveat, or question.
Miller et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: